Kye Pharmaceuticals

Kye is a growth-stage, specialty pharmaceutical company committed to bringing value to Canadians by identifying, licensing, and commercializing novel prescription medicines.

With a growing pipeline of innovative medicines, Kye’s portfolio spans a range of therapeutic areas including cardiology, psychiatry, pediatrics, rare diseases, hematology, and neurology. Our dedicated and experienced team perseveres to source marketed medicines from around the world that satisfy the unmet needs of Canadians. Currently, we are fiercely focused on supporting our treatments for attention deficit hyperactivity disorder (ADHD), Lambert-Eaton Myasthenic Syndrome (LEMS), symptomatic treatment of stable angina, major depressive disorder (MDD), and mild to moderate anemia. In addition to our current portfolio, we are very active in business development and plan to introduce many more innovative products in the years ahead.  Whether navigating marketing authorizations, tailoring commercialization strategies, or rethinking the business from the patient’s point of view, our goal is to support the health of Canadian patients and their families with medicines that matter.